Kenvue Inc. (NYSE:KVUE) Shares Purchased by GoalVest Advisory LLC

GoalVest Advisory LLC grew its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 35.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 94,897 shares of the company’s stock after purchasing an additional 24,835 shares during the period. GoalVest Advisory LLC’s holdings in Kenvue were worth $2,026,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the business. Benjamin F. Edwards & Company Inc. lifted its stake in shares of Kenvue by 4.7% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 43,744 shares of the company’s stock valued at $795,000 after purchasing an additional 1,971 shares during the period. AE Wealth Management LLC lifted its position in shares of Kenvue by 29.2% during the 2nd quarter. AE Wealth Management LLC now owns 15,259 shares of the company’s stock valued at $277,000 after acquiring an additional 3,453 shares during the period. Summit Trail Advisors LLC purchased a new stake in shares of Kenvue during the 2nd quarter worth approximately $258,000. Profund Advisors LLC grew its holdings in shares of Kenvue by 9.9% in the 2nd quarter. Profund Advisors LLC now owns 22,073 shares of the company’s stock worth $401,000 after acquiring an additional 1,987 shares during the period. Finally, DRW Securities LLC purchased a new position in Kenvue in the 2nd quarter valued at approximately $205,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Stock Performance

NYSE KVUE opened at $20.73 on Thursday. The business’s 50-day moving average price is $22.31 and its 200 day moving average price is $21.75. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.46. The company has a market capitalization of $39.75 billion, a PE ratio of 37.70, a price-to-earnings-growth ratio of 2.00 and a beta of 1.46.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The business had revenue of $3.90 billion for the quarter, compared to analysts’ expectations of $3.92 billion. During the same period last year, the company earned $0.31 earnings per share. The company’s quarterly revenue was down .4% on a year-over-year basis. On average, research analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be paid a $0.205 dividend. This represents a $0.82 annualized dividend and a dividend yield of 3.95%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue’s dividend payout ratio is currently 149.09%.

Wall Street Analysts Forecast Growth

KVUE has been the topic of a number of research analyst reports. Bank of America boosted their target price on Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a research report on Tuesday, October 22nd. UBS Group lowered their price objective on shares of Kenvue from $24.00 to $23.00 and set a “neutral” rating on the stock in a research note on Thursday, January 16th. Citigroup cut their target price on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research report on Wednesday, January 15th. Royal Bank of Canada upgraded shares of Kenvue from a “hold” rating to a “moderate buy” rating in a research report on Monday, December 9th. Finally, Barclays cut their price objective on Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research report on Friday, January 17th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, Kenvue has a consensus rating of “Hold” and an average target price of $23.08.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.